Evidence map›Paper›PMID 41084888›Full record

ArticleFuture microbiology2025

Proteomics and β-hydroxybutyrylome reveal the novel mechanisms underlying fluconazole resistance in

Li Zhang, Liuyang Cai, Yi Jin, Qiaoli Lv, Bin Xu, Kaiyuan Liu, Weihua Pan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Li ZhangDepartment of Dermatology, Shanghai Key Laboratory of Molecular Medical Mycology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, P. R. China.
Liuyang CaiDepartment of Dermatology, Shanghai Key Laboratory of Molecular Medical Mycology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, P. R. China.
Yi JinDepartment of Dermatology, Shanghai Key Laboratory of Molecular Medical Mycology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, P. R. China.
Qiaoli LvJiangxi Key Laboratory of Oncology, JXHC Key Laboratory of Tumour Metastasis, Jiangxi Cancer Hospital, the Second Affiliated Hospital of Nanchang Medical College, Jiangxi Cancer Institute, Nanchang, P. R. China.
Bin XuJiangxi Key Laboratory of Oncology, JXHC Key Laboratory of Tumour Metastasis, Jiangxi Cancer Hospital, the Second Affiliated Hospital of Nanchang Medical College, Jiangxi Cancer Institute, Nanchang, P. R. China.
Kaiyuan LiuDepartment of Bone Tumor Surgery, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P. R. China.
Weihua PanDepartment of Dermatology, Shanghai Key Laboratory of Molecular Medical Mycology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe rising incidence of fluconazole-resistant

aimTo delineate the proteomic and β-hydroxybutyrylome changes associated with fluconazole resistance and identify potential novel therapeutic approaches.

methodsWe performed comprehensive proteomic and β-hydroxybutyrylome analyses on fluconazole-resistant and -susceptible

resultsProteomic profiling exhibited significant dysregulation of acylation-modulating enzymes, notably downregulation of histone acetyltransferase RTT109 and upregulation of deacetylase HDA1. WB confirmed pronounced suppression of β-hydroxybutyrylation in the resistant strain. Combination therapy reduced the minimum inhibitory concentration values of fluconazole and BHB by 64-fold and 4-fold, respectively, indicating a synergistic interaction. β-hydroxybutyrylome profiling identified 27 significantly upregulated sites on 27 proteins and 91 downregulated sites on 86 proteins in the resistant strain, consistent with WB data. Bioinformatic analyses implicated alterations in β-hydroxybutyrylation of metabolic pathway proteins as a key mechanism underlying the development of fluconazole resistance.

conclusionFluconazole-resistant

Indexed as

3-Hydroxybutyric AcidAntifungal AgentsCandida albicansDrug Resistance, FungalFluconazoleFungal ProteinsProteomeAcylationHumansMicrobial Sensitivity TestsProteomics3-Hydroxybutyric AcidAntifungal AgentsFluconazoleFungal ProteinsProteomeCandida albicansfluconazoleproteomicsresistanceβ-hydroxybutyrylation

Identifiers

PMID41084888
PMCPMC12667677

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.